Aura Biosciences: Ocular Oncology Firm Under New Management Has Shot At Approval
Aura Biosciences May Offer Securities Up To $500M Aggregate; May Sell Up To $200M Common Stock Under Sales Agreement With Jefferies
HC Wainwright & Co. Maintains Buy on Aura Biosciences, Lowers Price Target to $18
Aura Biosciences Q2 EPS $(0.48) Misses $(0.38) Estimate
Aura Biosciences Announces 108 Patients Enrolled In The Phase 3 Trial Evaluating Belzupacap Sarotalocan As A Frontline Treatment For Patients With Early Choroidal Melanoma; Topline Data Expected In H2 2027
Aura Biosciences Q1 EPS $(0.50) Misses $(0.39) Estimate
Aura Biosciences Prices ~$260.3M Offering Of Common Shares, Pre-Funded Warrants
Aura Plans Share Sale With Option for Additional Stock Purchase
Aura Biosciences Names Natalie Holles as New CEO, Founder Elisabet de los Pinos, Ph.D. Steps Down, Nears Enrollment Completion for Late-Stage Cancer Trial
HC Wainwright & Co. Maintains Buy on Aura Biosciences, Raises Price Target to $24
Are Medical Stocks Lagging Aura Biosciences (AURA) This Year?
Does Aura Biosciences (AURA) Have the Potential to Rally 179.84% as Wall Street Analysts Expect?
Aura Biosciences, Inc. (AURA) Just Flashed Golden Cross Signal: Do You Buy?
Auranova Announces Closing of Private Placement of Flow-Through Shares
Is Aura Biosciences (AURA) Stock Outpacing Its Medical Peers This Year?
Wall Street Analysts Predict a 201.49% Upside in Aura Biosciences (AURA): Here's What You Should Know
Auranova Resources and Kenorland Minerals Commence Spring Drill Program at South Uchi Project
HC Wainwright & Co. Reiterates Buy on Aura Biosciences, Maintains $22 Price Target
Aura Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
Aura Biosciences Q4 EPS $(0.37) Beats $(0.45) Estimate
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.